Showing 1 - 20 of 30 Items
Showing 1 - 20 of 30 Items
Sort By: Relevance
Science Portal
v2.1.5758.produseast1
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
BACKGROUND
Strains of Mycobacterium tuberculosis Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approve... BACKGROUND New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci... BACKGROUND For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ... BACKGROUND Aft...2025-03-01 • IJTLD OPEN2025-03-01 • IJTLD OPEN2025-02-01 • Lancet Global Health2025-02-01 • Lancet Global Health2025-01-29 • New England Journal of Medicine2025-01-29 • New England Journal of Medicine2024-06-06 • Antimicrobial Agents and Chemotherapy2024-06-06 • Antimicrobial Agents and ChemotherapyRegimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled trial, TB-PRACTECAL, we inves...2024-05-16 • MSF Scientific Day International 20242024-05-16 • MSF Scientific Day International 20242024-05-16 • MSF Scientific Day International 20242024-05-16 • MSF Scientific Day International 2024INTRODUCTION
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...2024-03-20 • Clinical Infectious Diseases2024-03-20 • Clinical Infectious DiseasesBACKGROUND
Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include ...2024-02-01 • Lancet Respiratory Medicine2024-02-01 • Lancet Respiratory MedicineBACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...2024-01-29 • medRxiv2024-01-29 • medRxiv2023-12-01 • International Journal of Tuberculosis and Lung Disease2023-12-01 • International Journal of Tuberculosis and Lung DiseaseBACKGROUND
The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice.
METH...2023-10-24 • Clinical Infectious Diseases2023-10-24 • Clinical Infectious DiseasesBACKGROUND
Effectiveness, safety, tolerability and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel six-month oral regimens that include...2023-07-21 • Clinical Microbiology and Infection2023-07-21 • Clinical Microbiology and InfectionBACKGROUND
Tuberculosis is a global health challenge and one of the leading causes of death worldwide. In the last decade, the tuberculosis treatment landscape has dramatically chang...2023-06-07 • MSF Scientific Day International 20232023-06-07 • MSF Scientific Day International 20232022-06-07 • MSF Scientific Days International 2022No abstract available.2021-05-19 • MSF Scientific Days International 2021: Research2021-05-19 • MSF Scientific Days International 2021: Research2022-05-11 • MSF Scientific Days International 20222022-05-11 • MSF Scientific Days International 20222022-12-22 • New England Journal of Medicine2022-12-22 • New England Journal of MedicineBACKGROUND
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current...2022-04-01 • International Journal of Tuberculosis and Lung Disease2022-04-01 • International Journal of Tuberculosis and Lung Disease